A doctor-training account frames the experimental fat-reducing shot as a possible help against weight regain after GLP-1 treatment, which remains unproven.
Recap by typeshit. Post by @thedoctorpreneuracademy on Instagram.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
Levine argues lawyers and news coverage are getting ahead of the science on GLP-1 drugs and vision loss.
Trials showed low rates, while FAERS and EudraVigilance logged a wider range of events. The Warwick-linked authors call for standardized reporting and close monitoring.
Loading…